在最近有统计数据的5个交易日内，恆生中国企业（02828）、一脉阳光（02522）、南方恆生科技 （03033）港股通持股占比增加值最大，分别增加8.52%、4.91%、4.08%；东阳光药（06887）、锦欣生 殖（01951）、第四范式（06682）港股通持股占比减少值最大，分别减少-5.00%、-3.95%、-3.71%。 具体数据如下（交易所数据根据T+2日结算）： 1、港股通最新日占比增持榜（前20名） 智通财经APP获悉，根据2025年8月20日披露数据，京城机电股份（00187）、一脉阳光（02522）、安 井食品（02648）港股通持股占比增加值最大，分别增加3.04%、3.04%、1.93%；盈富基金（02800）、 锦欣生殖（01951）、山东墨龙（00568）港股通持股占比减少值最大，分别减 少-3.86%、-1.81%、-1.25%。 | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 京城机电股份(00187) | +3.04% | 45.45% | | 一脉阳光(02522) | +3.04% | 39.10% | | 安井食品(0264 ...

Core Insights - On August 19, 2025, Oriental Selection (01797), Tracker Fund of Hong Kong (02800), and Tencent Holdings (00700) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 7.043 billion, 5.106 billion, and 3.221 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Oriental Selection (01797), Hang Seng China Enterprises Index ETF (02828), and Tracker Fund of Hong Kong (02800) were the top three stocks, with trading amounts of 3.294 billion, 2.215 billion, and 2.021 billion respectively [1] Southbound Stock Connect - Top Active Companies - Oriental Selection (01797) had a trading amount of 7.043 billion with a net buy of -48.8231 million [2] - Tracker Fund of Hong Kong (02800) recorded a trading amount of 5.106 billion with a net buy of 5.089 billion [2] - Tencent Holdings (00700) had a trading amount of 3.221 billion with a net buy of 979 million [2] - Alibaba Group (09988) had a trading amount of 2.547 billion with a net buy of -7.2321 million [2] - SMIC (00981) recorded a trading amount of 2.084 billion with a net buy of 160.3 million [2] Shenzhen-Hong Kong Stock Connect - Top Active Companies - Oriental Selection (01797) had a trading amount of 3.294 billion with a net buy of -464 million [2] - Hang Seng China Enterprises Index ETF (02828) recorded a trading amount of 2.215 billion with a net buy of 2.215 billion [2] - Tracker Fund of Hong Kong (02800) had a trading amount of 2.021 billion with a net buy of 1.982 billion [2] - Tencent Holdings (00700) recorded a trading amount of 2.018 billion with a net buy of 46.322 million [2] - Alibaba Group (09988) had a trading amount of 1.984 billion with a net buy of 268 million [2]

Group 1 - The Hong Kong stock market's new consumption concept stocks experienced a widespread decline, with notable drops in several companies [1] - Blucco (00325) saw a significant decrease of 8.27%, closing at 112.000 [2] - Other companies such as Laopu Gold (06181) and Pop Mart (09992) also faced declines of 3.44% and 2.32% respectively [2] Group 2 - Additional companies in the new consumption sector, including Qi (02517) and Weilon Delicious (09982), reported declines of 2.50% and 2.12% respectively [2] - Xpeng Motors (09868) and Li Auto (02015) experienced minor declines of 1.66% and 1.51% [2] - Other companies like Juzhi Biotechnology (02367) and Mijue Group (02097) also showed slight decreases, indicating a broader trend in the market [2]

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - 京城机电股份 (00187) saw the largest increase in holdings, up by 2.42%, bringing its total to 49.96% [2]. - 一脉阳光 (02522) experienced a 1.76% increase, resulting in a holding of 35.32% [2]. - 微盟集团 (02013) had a 1.13% increase, with a current holding of 33.76% [2]. - In the last five trading days, 长飞光纤光缆 (06869) had the highest increase at 4.25%, now holding 55.68% [4]. - FORTIOR TECHNOLOGY (SHENZHEN) CO., LTD. (01304) increased by 3.12%, reaching 6.02% [4]. Group 2: Decreased Holdings - 荣昌生物 (09995) experienced the largest decrease in holdings, down by 3.69%, now at 51.39% [2]. - 东阳光药 (06887) saw a reduction of 0.92%, with a holding of 47.90% [2]. - 山东墨龙 (00568) decreased by 0.88%, now at 56.49% [2]. - Over the last five trading days, 东阳光药 (06887) had the most significant drop at 5.14%, bringing its holding to 47.90% [4]. - 凯莱英 (06821) decreased by 4.46%, now holding 46.14% [4].

Core Viewpoint - The company reported a significant increase in mid-term performance for the six months ending June 30, 2025, with revenue reaching 467 million RMB, a year-on-year increase of 12.89% [1] Financial Performance - Revenue for the reporting period was 467 million RMB, with a gross profit of 137 million RMB [1] - Shareholder profit attributable to the company was 16.44 million RMB, reflecting a substantial year-on-year increase of 328.65% [1] - Basic earnings per share were reported at 0.046 RMB [1] Business Strategy and Market Position - The increase in revenue was primarily driven by a rise in customer numbers, despite macroeconomic slowdowns and adjustments in the reform process [1] - The company maintained stable revenue growth in its core imaging center services, even amidst industry cyclical adjustments [1] - The company is actively adjusting its business pace and expanding its medical imaging center network through investments, mergers, and the incubation of industrial funds [1] Future Outlook - New imaging center projects are expected to gradually commence operations in the second half of 2025 [1] - The ongoing release of national medical infrastructure policies is anticipated to boost business revenue significantly, with a recovery in demand for medical equipment expected by the end of 2024 [1] - The company is developing more flexible and diverse products, which have led to a notable increase in customer numbers, injecting new vitality into revenue growth [1]

一脉阳光(02522.HK)发布截至2025年6月30日止六个月的中期业绩，收入4.67亿元(人民币，下同)，同比 增加12.89%;毛利1.37亿元;股东应占溢利1644.3万元，同比增加328.65%;每股基本盈利0.046元。 本文源自：金融界AI电报 ...

Core Insights - The company reported a revenue of 467 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 12.89% [1] - The gross profit was 137 million RMB, and the profit attributable to shareholders was 16.44 million RMB, which is a significant increase of 328.65% year-on-year [1] - Basic earnings per share stood at 0.046 RMB [1] Revenue Growth Drivers - The increase in revenue was primarily driven by a rise in the number of clients [1] - Core imaging center service revenue remained stable despite macroeconomic slowdowns and adjustments due to deepening reforms, maintaining growth compared to the second half of 2024 [1] Strategic Initiatives - The company proactively adjusted its business pace in response to industry cyclical adjustments, focusing on expanding its medical imaging center network through investments, acquisitions, and industrial fund incubation [1] - Higher quality operational management is being implemented for existing imaging center projects, while new centers are being constructed with a more refined approach [1] - New imaging center projects are expected to gradually commence operations in the second half of 2025 [1] Market Opportunities - The ongoing release of national medical infrastructure policies is expected to boost business revenue significantly, with a gradual recovery in demand for medical equipment updates starting from the end of 2024 [1] - The company is developing a more flexible and diverse range of products, which has led to a notable increase in client numbers, injecting new vitality into revenue growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 截至2025年6月30日止六個月的中期業績公告 董事會欣然宣佈本集團截至2025年6月30日止六個月的未經審核簡明綜合中期業 績，連同截至2024年6月30日止六個月的比較數字。 財務摘要 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 同比變動 | | | 未經審核 | 未經審核 | | | | 人民幣千元 | 人民幣千元 | | | 收入 | 467,049 | 413,713 | 12.9% | | 毛利 | 137,246 | 159,659 | -14.0% | | 期內溢利 | 15,834 | 962 | 1,545.9% | | 本公司擁有人應佔期 ...

Core Viewpoint - Yipai Sunshine (02522) has seen a significant stock price increase, with a rise of nearly 14% and a current price of 22.2 HKD, driven by positive earnings expectations and strong market performance [1] Financial Performance - The company is expected to report mid-year revenue between 450 million to 480 million RMB, reflecting a year-on-year growth of approximately 8.77% to 16.03% [1] - Projected net profit is estimated to be between 14.5 million to 16.5 million RMB, indicating a substantial year-on-year increase of approximately 1350% to 1550% [1] Business Growth Drivers - The increase in revenue is attributed to a rise in both the number of clients and the services delivered by the company [1] - The significant growth in net profit is primarily due to increased revenue compared to the same period in 2024 and a reduction in administrative expenses [1] Industry Position - Yipai Sunshine is recognized as a leading player in the domestic medical imaging service sector, with a steady expansion strategy [1] - The company is developing smart imaging comprehensive solutions in the AI era, facilitating data monetization and application pathways [1] - There is a positive outlook on the company's long-term development potential as noted by Guosen Securities [1]

Core Viewpoint - The company Yipai Yangguang (02522) has seen a significant stock price increase, rising nearly 14% and currently trading at 22.2 HKD, with a trading volume of 1.016 billion HKD. The upcoming board meeting on August 18 is set to approve the mid-year performance, with projected revenue and profit showing substantial growth compared to the previous year [1]. Financial Performance - The company expects revenue for the first half of the year to be between 450 million to 480 million RMB, representing a year-on-year growth of approximately 8.77% to 16.03% [1]. - Projected net profit is estimated to be between 14.5 million to 16.5 million RMB, indicating a remarkable year-on-year increase of approximately 1350% to 1550% [1]. Business Growth Drivers - The increase in revenue is attributed to a rise in the number of clients and the services delivered by the company [1]. - The significant growth in net profit is primarily due to the increase in revenue compared to the same period in 2024 and a reduction in administrative expenses [1]. Industry Position - Yipai Yangguang is recognized as a leading player in the domestic medical imaging service sector, with a steady expansion strategy [1]. - The company is developing smart imaging comprehensive solutions in the AI era, facilitating data monetization and application pathways, which enhances its long-term growth potential [1].